Emerging research suggest this peptide, a dual agonist targeting both incretin and GIP , appears to provide a significant advancement for weight management . Preliminary human trials have demonstrated considerable reductions in visceral mass , potentially surpassing existing body composition treatments. Despite this, more study is needed to fully a